Details of the Drug Reposition

General Information of This Drug (ID: DMYIXQZ)

Drug Name
LP-108   DMYIXQZ

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Myelodysplastic syndrome DISYHNUI 2A37 Phase 1 [1]
Chronic myelomonocytic leukaemia DISDN5P7 2A40 Phase 1 [1]
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 1 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04139434) Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). U.S. National Institutes of Health.